Ichnos Sciences welcomes collaboration with partners that have bold ideas and capabilities that complement and stretch our potential to shift progress, advance science, and deliver transformative medicines.
Ichnos is committed to advancing our clinical-stage oncology portfolio and the next wave of discovery-stage assets. We are looking for partners who are interested in collaborating with us as we work to bring multispecific antibodies to patients with hematologic cancers and solid tumors.
Interested in partnering? Connect with us at our Contact Us page
Ichnos is out-licensing two assets that were developed to treat a range of autoimmune diseases with high unmet need.
Asset / MOA | Status | Licensee |
---|---|---|
|
|
![]() |
|
|
|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.